Clinical Trials

• Randomized Phase II trial of low-dose continuous chemotherapy (cyclophosphamide and methotrexate) with and without bevacizumab (Harold Burstein, MD, PhD, DFCI, Principal Investigator).
• Neoadjuvant chemotherapy in palpable breast cancer: evaluation of physiologic, radiologic, and molecular markers in predicting response (Alphonse Taghian, MD, PhD, MGH, Principal Investigator).